CoChat

The Development of Cannabinoid Based Therapies for Epilepsy

J. Hill, Andrew, D.M. Hill, Thomas, J. Whalley, Benjamin · 2013 · Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features
Cited by 20

The DOI matches its Crossref record.

Abstract

Epilepsy is a chronic, progressive, neurological disorder affecting ~0.5-1% of the population for which there is no cure. Furthermore, efficacious seizure suppression is yet to be achieved for all patients; ~35% of people with epilepsy (PWE) have seizures pharmacoresistant to existing drugs. In this regard, the endocannabinoid system (ECS) is an attractive therapeutic target as it can limit synaptic transmission to oppose hyperexcitability in addition to central cannabinoid type-2 receptor (CB2R) modulation potentially limiting neuronal death associated with epilepsy. Postsynaptic endocannabinoid (eCB) synthesis is stimulated by excitatory neurotransmission, eCBs then act retrogradely via presynaptic cannabinoid type-1 receptors (CB1R) to suppress subsequent excitatory (glutamatergic) and inhibitory (GABAergic) synaptic activity close to the synthetic locus. Thus, eCBs can limit excessive excitation but also hinder inhibitory processes such that their effects on epileptic foci and the spread of seizure activity is dependent on the relative proportions of excitatory and inhibitory synapses, and their organisation into local and global circuits within the CNS. Cannabis has a history of antiepileptic use that continues to the present day in medical marijuana programmes, and CB1R receptor agonism, either by medical marijuana, pure Δ9-tetrahydrocannabinol (Δ9-THC) or synthetic CB1R ligands, can be anticonvulsant in humans and in in vitro and in vivo seizure models, but paradoxically can cause seizures in healthy rodents. Furthermore, it is clear that other cannabis constituents are anti-epileptic, and, whilst the mechanisms by which they act remain undetermined, they certainly extend beyond ECS modulation. Moreover, whilst CB1R agonism can control seizures in some patients and many animal seizure models, it is unlikely to represent a widely exploitable target for seizure control due to its psychoactive sequelae. Conversely, many non-Δ9-THC plant cannabinoids are inactive at CB1R or CB2R at therapeutically relevant concentrations and a subset of these (e.g. cannabidiol) exert significant anticonvulsant effects in numerous animal models of seizure at clinically promising doses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/9781608050284113010011

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 20

Metadata

Authors
J. Hill, A., D.M. Hill, T., & J. Whalley, B.
Venue
Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features
Published
2013-09-04
Pages
164-204
OpenAlex
W2194300967
Cited by
20
References
0
FWCI
6.35
Type
book chapter
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Development of Cannabinoid Based Therapies for Epilepsy. https://app.cochat.ai/papers/10.2174/9781608050284113010011
The paper
J. Hill, A., D.M. Hill, T., & J. Whalley, B. (2013). The Development of Cannabinoid Based Therapies for Epilepsy. Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features. https://doi.org/10.2174/9781608050284113010011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.